Plus Therapeutics Presents REYOBIQ Clinical Data at AANS Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2026
0mins
Source: Newsfilter
- Clinical Data Highlights: At the 2026 AANS Annual Meeting, Plus Therapeutics presented data from the Phase 1 ReSPECT-LM trial of REYOBIQ, showing a median overall survival of approximately 9 months at the recommended Phase 2 dose, significantly better than the historical range of 2-6 months, indicating the therapy's potential for patients with leptomeningeal metastases lacking FDA-approved treatments.
- Anti-Tumor Activity: The study demonstrated robust anti-tumor activity, including significant reductions in circulating tumor cells (CTC) and clinical benefits, supporting the advancement of REYOBIQ into later-stage clinical development and potentially offering new treatment options for patients.
- Safety and Tolerability: REYOBIQ exhibited a favorable safety and tolerability profile, which supports its progression into later-stage clinical trials, with a target-to-off-target absorbed dose ratio exceeding 100:1, minimizing exposure to healthy tissue.
- Immune Remodeling Potential: Translational analyses indicated that REYOBIQ may induce immune remodeling within the tumor microenvironment, including activation of CD8+ T cells and enhancement of anti-tumor immune responses, supporting potential future combination strategies with immunotherapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSTV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSTV
Wall Street analysts forecast PSTV stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.920
Low
2.00
Averages
8.00
High
19.00
Current: 3.920
Low
2.00
Averages
8.00
High
19.00
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Plus Therapeutics Rebrands to Cerenome, New Ticker CNSY Effective August 3, 2026
- Corporate Rebranding: Plus Therapeutics announced its rebranding to Cerenome effective August 3, 2026, with a new Nasdaq ticker CNSY, aimed at better reflecting its identity as an integrated CNS oncology platform, which is expected to enhance market recognition and investor confidence.
- 2026 Milestones Affirmed: The company reaffirmed its key milestones for 2026, including advancing REYOBIQ clinical trials and commercializing the CNSide diagnostics business, which is anticipated to drive sustained revenue growth and increase market share.
- CNSide Commercial Progress: The CNSide diagnostic platform achieved significant market expansion in the first half of 2026, increasing covered lives from 67 million to 126 million, with a goal to exceed 150 million by year-end, thereby strengthening the company's competitive position in CNS cancer management.
- AI Strategy Implementation: The company is advancing its native AI strategy, aimed at improving operational efficiency through proprietary workflows and data infrastructure, which will support clinical execution and lay the groundwork for future partnership opportunities.
See More
Plus Therapeutics Signs Agreement with Elevance Health for CNSide Assay
- Agreement Signed: Plus Therapeutics' wholly owned subsidiary CNSide Diagnostics has signed a national agreement with Elevance Health, effective May 1, 2026, marking a strategic expansion in tumor cell enumeration testing.
- Testing Platform Benefits: The CNSide CSF assay platform determines leptomeningeal metastases in patients, utilizing quantitative analyses to detect malignant cell residues, and has proven effective in the FORESEE clinical trial with 92% sensitivity and 95% specificity.
- Market Coverage Expansion: The contract with Elevance is expected to add 45.5 million users, bringing total coverage to 126 million people across the U.S., significantly enhancing market penetration and brand influence.
- Positive Stock Reaction: PSTV closed at $4.26, up 7.58%, and is trading at $4.28 in pre-market, indicating strong market expectations regarding this partnership.
See More
Plus Therapeutics Partners with Elevance Health for Cancer Screening Test Coverage Expansion
- Agreement Reached: Plus Therapeutics' subsidiary CNSide Diagnostics has signed an agreement with Elevance Health to expand coverage for a cancer screening test, allowing Elevance members to get reimbursed for the CNSide test, benefiting approximately 45.4 million people in the U.S.
- Test Overview: The CNSide test is designed to help patients identify whether their tumor cells have spread to the central nervous system, currently available exclusively through CNSide Diagnostics to U.S. healthcare professionals, enhancing market recognition of the test.
- Expanded Coverage: The agreement takes effect on May 1, 2026, and is expected to widen the test's availability to 126 million people, significantly boosting Plus Therapeutics' competitiveness in the cancer screening market.
- Market Impact: This agreement not only enhances Plus Therapeutics' market position but may also drive its stock price up, reflecting investor confidence in the company's future growth potential.
See More
CNSide Diagnostics Signs National Agreement with Elevance Health Covering 45.4 Million People
- Expanded Coverage Agreement: CNSide Diagnostics has signed a national agreement with Elevance Health effective May 1, 2026, covering approximately 45.4 million people, which increases the total contracted coverage for the CNSide CSF TCE assay to 126 million, significantly enhancing the company's market presence in the U.S.
- Clinical Utility Validation: The CNSide® CSF assay platform has demonstrated superior clinical utility over standard care in nine peer-reviewed publications and the FORESEE clinical trial, with over 11,000 tests performed at more than 120 U.S. cancer institutions since 2020, achieving 92% sensitivity and 95% specificity, influencing treatment decisions in 90% of cases.
- Market Exclusivity: The CNSide® testing service is exclusively provided through CNSide Diagnostics, ensuring its unique position in the central nervous system tumor cell detection market and further solidifying the company's competitive advantage in cancer diagnostics.
- Strategic Growth Potential: This agreement not only expands market coverage for the assay but also provides Plus Therapeutics with opportunities to further develop and commercialize its targeted radiotherapeutic products, driving long-term growth in the challenging cancer treatment landscape.
See More
Plus Therapeutics Announces Business Update Conference Call
- Business Update Call: Plus Therapeutics will host a business update conference call on June 30, 2026, at 8:30 a.m. Eastern Time, focusing on the launch of its CNSide® diagnostic and the integrated development plan for its lead drug Reyobiq, aiming to enhance its market position in CNS cancers.
- Strategic Focus: Management will elaborate on its CNS oncology strategy and native AI development plans, indicating substantial progress in diagnostics, therapeutics, and AI, which is expected to improve outcomes for CNS cancer patients.
- Investor Relations: A replay of the webcast will be available on the company's website post-event, ensuring investors can access the latest information promptly, thereby enhancing transparency and shareholder value.
- Forward-Looking Statements: The press release includes forward-looking statements regarding clinical operations and expected commercial activities, highlighting risks and uncertainties related to maintaining regulatory accreditations and successfully commercializing the CNSide CSF Assay Platform.
See More
CNSide Diagnostics Achieves CAP Accreditation for Enhanced Testing Standards
- Laboratory Accreditation Milestone: CNSide Diagnostics' Houston laboratory has received accreditation from the College of American Pathologists (CAP), signifying adherence to rigorous standards in clinical protocols, quality control, and personnel qualifications, which is expected to enhance the company's competitive position in CNS cancer diagnostics.
- Quality Framework Enhancement: The CAP accreditation further strengthens CNSide Diagnostics' quality framework, enabling the delivery of the highest standard of testing services to clinicians and patients while supporting broader payer coverage and reimbursement, facilitating the company's expansion in the U.S. market.
- Increased Clinical Confidence: By providing additional assurance regarding the analytical and operational quality of the CNSide® CSF testing platform, CAP accreditation is set to bolster the confidence of oncologists and neuro-oncologists, promoting its adoption within healthcare systems.
- Future Development Potential: The CAP accreditation lays a quality foundation for CNSide Diagnostics to support the expansion of future laboratory-developed tests, indicating the company's ongoing innovation and leadership in CNS cancer diagnostics.
See More
Plus Therapeutics Rebrands to Cerenome, New Ticker CNSY Effective August 3, 2026
- Corporate Rebranding: Plus Therapeutics announced its rebranding to Cerenome effective August 3, 2026, with a new Nasdaq ticker CNSY, aimed at better reflecting its identity as an integrated CNS oncology platform, which is expected to enhance market recognition and investor confidence.
- 2026 Milestones Affirmed: The company reaffirmed its key milestones for 2026, including advancing REYOBIQ clinical trials and commercializing the CNSide diagnostics business, which is anticipated to drive sustained revenue growth and increase market share.
- CNSide Commercial Progress: The CNSide diagnostic platform achieved significant market expansion in the first half of 2026, increasing covered lives from 67 million to 126 million, with a goal to exceed 150 million by year-end, thereby strengthening the company's competitive position in CNS cancer management.
- AI Strategy Implementation: The company is advancing its native AI strategy, aimed at improving operational efficiency through proprietary workflows and data infrastructure, which will support clinical execution and lay the groundwork for future partnership opportunities.
See More
Plus Therapeutics Signs Agreement with Elevance Health for CNSide Assay
- Agreement Signed: Plus Therapeutics' wholly owned subsidiary CNSide Diagnostics has signed a national agreement with Elevance Health, effective May 1, 2026, marking a strategic expansion in tumor cell enumeration testing.
- Testing Platform Benefits: The CNSide CSF assay platform determines leptomeningeal metastases in patients, utilizing quantitative analyses to detect malignant cell residues, and has proven effective in the FORESEE clinical trial with 92% sensitivity and 95% specificity.
- Market Coverage Expansion: The contract with Elevance is expected to add 45.5 million users, bringing total coverage to 126 million people across the U.S., significantly enhancing market penetration and brand influence.
- Positive Stock Reaction: PSTV closed at $4.26, up 7.58%, and is trading at $4.28 in pre-market, indicating strong market expectations regarding this partnership.
See More
Plus Therapeutics Partners with Elevance Health for Cancer Screening Test Coverage Expansion
- Agreement Reached: Plus Therapeutics' subsidiary CNSide Diagnostics has signed an agreement with Elevance Health to expand coverage for a cancer screening test, allowing Elevance members to get reimbursed for the CNSide test, benefiting approximately 45.4 million people in the U.S.
- Test Overview: The CNSide test is designed to help patients identify whether their tumor cells have spread to the central nervous system, currently available exclusively through CNSide Diagnostics to U.S. healthcare professionals, enhancing market recognition of the test.
- Expanded Coverage: The agreement takes effect on May 1, 2026, and is expected to widen the test's availability to 126 million people, significantly boosting Plus Therapeutics' competitiveness in the cancer screening market.
- Market Impact: This agreement not only enhances Plus Therapeutics' market position but may also drive its stock price up, reflecting investor confidence in the company's future growth potential.
See More
CNSide Diagnostics Signs National Agreement with Elevance Health Covering 45.4 Million People
- Expanded Coverage Agreement: CNSide Diagnostics has signed a national agreement with Elevance Health effective May 1, 2026, covering approximately 45.4 million people, which increases the total contracted coverage for the CNSide CSF TCE assay to 126 million, significantly enhancing the company's market presence in the U.S.
- Clinical Utility Validation: The CNSide® CSF assay platform has demonstrated superior clinical utility over standard care in nine peer-reviewed publications and the FORESEE clinical trial, with over 11,000 tests performed at more than 120 U.S. cancer institutions since 2020, achieving 92% sensitivity and 95% specificity, influencing treatment decisions in 90% of cases.
- Market Exclusivity: The CNSide® testing service is exclusively provided through CNSide Diagnostics, ensuring its unique position in the central nervous system tumor cell detection market and further solidifying the company's competitive advantage in cancer diagnostics.
- Strategic Growth Potential: This agreement not only expands market coverage for the assay but also provides Plus Therapeutics with opportunities to further develop and commercialize its targeted radiotherapeutic products, driving long-term growth in the challenging cancer treatment landscape.
See More
Plus Therapeutics Announces Business Update Conference Call
- Business Update Call: Plus Therapeutics will host a business update conference call on June 30, 2026, at 8:30 a.m. Eastern Time, focusing on the launch of its CNSide® diagnostic and the integrated development plan for its lead drug Reyobiq, aiming to enhance its market position in CNS cancers.
- Strategic Focus: Management will elaborate on its CNS oncology strategy and native AI development plans, indicating substantial progress in diagnostics, therapeutics, and AI, which is expected to improve outcomes for CNS cancer patients.
- Investor Relations: A replay of the webcast will be available on the company's website post-event, ensuring investors can access the latest information promptly, thereby enhancing transparency and shareholder value.
- Forward-Looking Statements: The press release includes forward-looking statements regarding clinical operations and expected commercial activities, highlighting risks and uncertainties related to maintaining regulatory accreditations and successfully commercializing the CNSide CSF Assay Platform.
See More
CNSide Diagnostics Achieves CAP Accreditation for Enhanced Testing Standards
- Laboratory Accreditation Milestone: CNSide Diagnostics' Houston laboratory has received accreditation from the College of American Pathologists (CAP), signifying adherence to rigorous standards in clinical protocols, quality control, and personnel qualifications, which is expected to enhance the company's competitive position in CNS cancer diagnostics.
- Quality Framework Enhancement: The CAP accreditation further strengthens CNSide Diagnostics' quality framework, enabling the delivery of the highest standard of testing services to clinicians and patients while supporting broader payer coverage and reimbursement, facilitating the company's expansion in the U.S. market.
- Increased Clinical Confidence: By providing additional assurance regarding the analytical and operational quality of the CNSide® CSF testing platform, CAP accreditation is set to bolster the confidence of oncologists and neuro-oncologists, promoting its adoption within healthcare systems.
- Future Development Potential: The CAP accreditation lays a quality foundation for CNSide Diagnostics to support the expansion of future laboratory-developed tests, indicating the company's ongoing innovation and leadership in CNS cancer diagnostics.
See More
